Abstract
Circulating tumor DNA (ctDNA) analysis is a promising approach for treatment response monitoring in patients with NSCLC. Additionally, comprehensive genomic profiling (CGP) is playing an integral role in the optimal management of this disease across stages. In this study, we analyzed patients with stage I-IV NSCLC who underwent serial monitoring with a personalized, tumor-informed ctDNA assay with or without concomitant CGP, with a focus on real-world feasibility and clinical utility.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
